Q1 2024 EPS Estimates for Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Decreased by Analyst

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Stock analysts at HC Wainwright dropped their Q1 2024 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research report issued on Monday, April 22nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.28) per share for the quarter, down from their previous estimate of ($0.27). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.04) EPS and FY2025 earnings at ($1.09) EPS.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Monday, April 15th. The company reported ($0.35) earnings per share (EPS) for the quarter.

Separately, Benchmark restated a “speculative buy” rating and issued a $17.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 16th.

Reviva Pharmaceuticals Stock Down 1.3 %

Shares of RVPH stock opened at $2.98 on Wednesday. The firm has a market cap of $83.20 million, a P/E ratio of -1.82 and a beta of -0.02. The business has a 50-day moving average price of $3.54 and a two-hundred day moving average price of $4.09. Reviva Pharmaceuticals has a 12-month low of $2.67 and a 12-month high of $9.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Vontobel Holding Ltd. bought a new stake in shares of Reviva Pharmaceuticals in the 4th quarter valued at about $72,000. EMC Capital Management lifted its position in Reviva Pharmaceuticals by 1,294.3% in the third quarter. EMC Capital Management now owns 123,915 shares of the company’s stock valued at $613,000 after purchasing an additional 115,028 shares during the last quarter. Finally, Armistice Capital LLC boosted its stake in shares of Reviva Pharmaceuticals by 194.0% during the fourth quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock valued at $9,085,000 after purchasing an additional 1,164,000 shares during the period. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.